一个路线图,精确治疗家族性肺纤维化
Killian Hurley1, Mari Ozaki1, Quentin Philippot2
1Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland; Tissue Engineering Research Group, Royal College of Surgeons in Ireland, Dublin 2, Ireland.
EBioMedicine
|May 8, 2024
概括
由于遗传因素,家族性肺纤维化 (FPF) 缺乏向治疗. 本文概述了一个框架,以解决研究差距,并为FPF开发精密疗法.
科学领域:
- 肺部医学 肺部医学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 间歇性肺部疾病 (ILD) 涵盖着各种肺部疾病,其特点是炎症,异常修复和纤维化,往往导致致命的呼吸衰竭.
- 遗传因素对ILD风险有显著的贡献,定义了家族性肺纤维化 (FPF). 单一的FPF形式经常表现出不良预后和对现有疗法的有限反应.
- 对于FPF的特定,针对变异的精确治疗,存在着严重的未满足需求,因为目前的干预措施对许多患者来说不足.
研究的目的:
- 建立一个全面的框架,解决FPF基础,翻译和临床研究的研究缺口.
- 确定开发临床前模型,新型治疗候选药物和创新的临床试验设计的关键领域.
- 总结专家工作组讨论,建议和关于FPF精密处理的悬而未决的问题.
主要方法:
- 召集专家工作组讨论FPF研究和治疗挑战.
- 综合目前关于FPF遗传基础和临床方面的知识.
- 在基础,转化和临床领域确定和优先考虑研究重点.
主要成果:
- 工作组在了解FPF病原和治疗反应方面发现了重大研究缺口.
- 未来发展的关键领域包括增强的临床前模型,新药标的识别和优化临床试验策略.
- 该论文强调,迫切需要精准医学方法,以适应FPF的遗传基础.
结论:
- 一个协调的,多学科的研究工作是必不可少的,以推进FPF的精密治疗.
- 开发向疗法需要更深入地了解FPF中的遗传变异及其功能后果.
- 这份立场文件为未来的研究工作提供了路线图,旨在改善FPF患者的结果.
相关概念视频
01:24Cystic Fibrosis: Management
155
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
155
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:20COPD: Pathogenesis and Clinical Features
263
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
263
01:28Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177